 Thyrotropin-releasing hormone analogues and their therapeutic applications |
| The present invention pertains to novel TRH analogues, compositions, and methods for the controlled ... |
|
| Probiotics in primary prevention of atopic diseases |
| What is claimed is: 1. A method for prevention of atopic diseases selected from the group ... |
|
| Humanin-like peptide and use thereof |
| The invention claimed is: 1. A polypeptide comprising an amino acid sequence as shown in SEQ ID NO: ... |
|
| Method of treating cardiovascular diseases |
| OF PREFERRED EMBODIMENTS As examples of the diseases which the method according to the invention ... |
|
| Rapid production of autologous tumor vaccines |
| In accordance with the present invention an autologous vaccine to tumor cells is produced by ... |
|
| Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| OF THE INVENTION In accordance with the invention novel therapeutic use is provided for certain ... |
|
| Engineered protein kinases which can utilize modified nucleotide triphosphate substrates |
| OF THE INVENTION Inhibition of Engineered Kinases FIG. 9 shows a schematic representation of an ... |
|
| Method for the production of bacterial toxins |
| The present invention is based upon the discovery that bacterial toxin expression inhibitors ... |
|
| Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof |
| OF PREFERRED EMBODIMENTS In its preferred embodiments, this invention involves preparation and ... |
|
|
Recombinant allergenic proteins from ragweed pollen
| Details |
Inventors: Rogers, Bruce; Klapper, David G.; Rafnar, Thorunn; Kuo, Mei-chang;
Assignee: ImmuLogic Pharmaceutical Corporation (Waltham, MA); University of North Carolina at Chapel Hill (Chapel Hill, NC)
Primary Examiner: Feisee; Lila
Assistant Examiner: Reeves; Julie E.
Attorney, Agent or Firm: Lahive & Cockfield, LLP
Antigen E or Amb a I of ragweed pollen has been shown to be a family or families of proteins. cDNAs encoding Amb a I, the major human allergen of ragweed and Amb a II, peptides derived from Amb a I or Amb a II, antibodies against the peptides; and methods of treating individuals for sensitivity to ragweed are disclosed. |
|
DETAILED DESCRIPTION The present invention relates to allergenic proteins or peptides from ragweed, DNAs encoding all or a portion of such allergenic proteins or peptides; to compositions containing such an allergen(s) or portions of the allergen(s); and to methods of administering the allergen(s) or a portion thereof or a composition which includes the allergen(s) or portions thereof to reduce or prevent the adverse effects that exposure to the allergen normally has on ragweed-sensitive individuals (i.
e.
, to desensitize individuals to the allergen or block the effects of the allergen).
The present invention further relates to methods of diagnosing sensitivity to ragweed pollen.
It has now been shown that Antigen E or Amb a I is not a single protein but, rather, a family or families of proteins to which ragweed-sensitive individuals react.
In particular, the present invention relates to DNA encoding an amino acid sequence or peptide present in allergenic proteins from ragweed pollen.
It relates to DNA encoding all or a portion of the ragweed allergen Amb a I or Antigen E preparation which has been isolated.
Such ragweed allergen preparations are heterogeneous in nature and may include, in addition to what is currently referred to as Amb a I or Antigen E, other ragweed components which are allergenic (i.
e.
, cause the typical adverse effects observed in a ragweed-sensitive individual upon exposure to ragweed pollen).
These may include, for example, what is referred to in the literature as Antigen K and referred to herein as Amb a II.
The present invention also relates to DNAs encoding similar amino acid sequences (i.
e.
, DNA encoding amino acid sequences of allergens) in types of ragweed other than short ragweed, such as giant ragweed and western ragweed.
|
| Related patents |
|
|
Nucleic acids encoding allergenic proteins from ragweed
The present invention relates to allergenic proteins or peptides from ragweed, DNAs encoding all or a portion of such allergenic proteins or peptides; to compositions ...
|
|
|
Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
OF THE INVENTION As used herein and in the claims, the term "animal" means mammals and avians, with humans being the animal of greatest interest. As used herein and in ...
|
|
|
Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
What is claimed is: 1. An isolated and purified DNA molecule encoding a hybrid protein, said hybrid protein comprising a heterologous polypeptide attached to the N-...
|
|
|
Lentiviral packaging constructs
OF THE INVENTION The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, molecular biology, cell culture,...
|
|
|
Method for measuring no synthase activity
OF THE INVENTION In the context of the present invention the following definitions apply: Incubation: the introduction and leaving of a biological object, such as an ...
|
|
|
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
In one aspect, the present invention pertains to the discovery herein that Wnt polypeptides ("Wnts"), such as Wnt-5a, play a role in hematopoiesis. In another aspect, ...
|
|
|
Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
The invention relates to a composition for delivery of a virus vector to an animal cell. The composition comprises a hydrogel precursor mixture having the virus vector ...
|
|
|
Particle delivery techniques
OF THE PREFERRED EMBODIMENTS The practice of the present invention will employ, unless otherwise indicated, conventional methods of molecular biology and recombinant DNA...
|
|
|
Tissue anchor system
The invention claimed is: 1. An adjustable tissue anchor comprising: a. an anchor body having a first and second open end with an interior chamber running between said ...
|
|
|
Ribozyme mediated inactivation of the androgen receptor
The present invention describes inactivation of AR gene expression by engineering hammerhead ribozymes to cleave specific sites in AR mRNA. The present in vitro studies ...
|
|
|
Gene Therapy 
